| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2019-04-12 |
| タイトル |
|
|
タイトル |
Anti-tumor effects of a nonsteroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression. |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.24517/00053846 |
|
ID登録タイプ |
JaLC |
| 著者 |
Higuchi, Takashi
Takeuchi, Akihiko
Munesue, Seiichi
Yamamoto, Norio
Hayashi, Katsuhiro
Kimura, Hiroaki
Miwa, Shinji
Inaki, Hiroyuki
Shimozaki, Shingo
Kato, Takashi
Aoki, Yu
Abe, Kensaku
Taniguchi, Yuta
Aiba, Hisaki
Murakami, Hideki
Harashima, Ai
Yamamoto, Yasuhiko
Tsuchiya, Hiroyuki
|
| 著者別表示 |
武内, 章彦
棟居, 聖一
山本, 憲男
林, 克洋
三輪, 真嗣
谷口, 裕太
原島, 愛
山本, 靖彦
土屋, 弘行
|
| 提供者所属 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
金沢大学医薬保健研究域医学系 |
| 書誌情報 |
Cancer Medicine
巻 7,
号 5,
p. 1944-1954,
発行日 2018-05
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2045-7634 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1002/cam4.1438 |
| 出版者 |
|
|
出版者 |
Wiley-Blackwell |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Surgical resection is the only treatment for chondrosarcomas, because of their resistance to chemotherapy and radiotherapy; therefore, additional strategies are crucial to treat chondrosarcomas. Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor, which has been reported as a possible therapeutic target in certain malignancies including chondrosarcomas. In this study, we demonstrated that a nonsteroidal anti-inflammatory drug, zaltoprofen, could induce PPARγ activation and elicit anti-tumor effects in chondrosarcoma cells. Zaltoprofen was found to induce expressions of PPARγ mRNA and protein in human chondrosarcoma SW1353 and OUMS27 cells, and induce PPARγ-responsible promoter reporter activities. Inhibitory effects of zaltoprofen were observed on cell viability, proliferation, migration, and invasion, and the activity of matrix metalloproteinase-2 (MMP2); these effects were dependent on PPARγ activation and evidenced by silencing PPARγ. Moreover, we showed a case of a patient with cervical chondrosarcoma (grade 2), who was treated with zaltoprofen and has been free from disease progression for more than 2 years. Histopathological findings revealed enhanced expression of PPARγ and reduced expression of MMP2 after administration of zaltoprofen. These findings demonstrate that zaltoprofen could be a promising drug against the malignant phenotypes in chondrosarcomas via activation of PPARγ and inhibition of MMP2 activity. © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
29573200 |
| 権利 |
|
|
権利情報 |
Copyright © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 関連URI |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1438 |
|
|
関連名称 |
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1438 |
ME-PR-MUNESUE-S-1944.pdf (690.6 kB)
.png)
